Greenwich LifeSciences, Inc. (GLSI)
20.58
+1.88
(+10.05%)
USD |
NASDAQ |
Nov 18, 16:00
20.58
0.00 (0.00%)
After-Hours: 20:00
Greenwich LifeSciences Enterprise Value : 296.18M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 296.18M |
| November 17, 2026 | 268.58M |
| November 16, 2026 | 196.07M |
| November 13, 2026 | 213.39M |
| November 12, 2026 | 218.38M |
| November 11, 2026 | 230.27M |
| November 10, 2026 | 229.98M |
| November 09, 2026 | 236.59M |
| November 06, 2026 | 216.77M |
| November 05, 2026 | 209.14M |
| November 04, 2026 | 234.09M |
| November 03, 2026 | 227.78M |
| November 02, 2026 | 235.70M |
| October 30, 2026 | 249.65M |
| October 29, 2026 | 272.99M |
| October 28, 2026 | 262.86M |
| October 27, 2026 | 249.80M |
| October 26, 2026 | 245.47M |
| October 23, 2026 | 229.39M |
| October 22, 2026 | 221.32M |
| October 21, 2026 | 237.32M |
| October 20, 2026 | 232.48M |
| October 19, 2026 | 217.36M |
| October 16, 2026 | 207.67M |
| October 15, 2026 | 218.97M |
| Date | Value |
|---|---|
| October 14, 2026 | 220.15M |
| October 13, 2026 | 221.61M |
| October 12, 2026 | 254.93M |
| October 09, 2026 | 236.73M |
| October 08, 2026 | 216.33M |
| October 07, 2026 | 220.00M |
| October 06, 2026 | 225.87M |
| October 05, 2026 | 242.31M |
| October 02, 2026 | 243.34M |
| October 01, 2026 | 248.77M |
| September 30, 2026 | 259.04M |
| September 29, 2026 | 260.91M |
| September 28, 2026 | 263.99M |
| September 25, 2026 | 258.56M |
| September 24, 2026 | 256.80M |
| September 23, 2026 | 248.14M |
| September 22, 2026 | 277.05M |
| September 21, 2026 | 264.06M |
| September 18, 2026 | 269.86M |
| September 17, 2026 | 261.06M |
| September 16, 2026 | 220.54M |
| September 15, 2026 | 227.30M |
| September 14, 2026 | 226.71M |
| September 11, 2026 | 217.90M |
| September 10, 2026 | 212.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 473.01M |
| Amgen, Inc. | 280.92B |
| Anika Therapeutics, Inc. | 163.62M |
| BioCryst Pharmaceuticals, Inc. | 2.322B |
| Imunon, Inc. | 6.500M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.814M |
| Total Expenses (Quarterly) | 5.814M |
| EPS Diluted (Quarterly) | -0.3961 |
| Earnings Yield | -7.82% |
| Normalized Earnings Yield | -7.816 |